article thumbnail

Adherence to optimal medical therapy and control of cardiovascular risk factors in patients after ST elevation myocardial infarction in Mexico

Frontiers in Cardiovascular Medicine

IntroductionIn developing countries, there is a notable scarcity of real-world data on adherence to optimal medical therapy (OMT) and its correlation with major cardiovascular adverse events (MACEs) after ST-elevation myocardial infarction (STEMI). Patients were followed up for 4.5 ResultsWe included 349 patients with a mean age of 58.08

article thumbnail

Higher Risk of Myocardial Infarction, Heart Failure, and Atrial Fibrillation Noted After Spinal Cord Injury

All About Cardiovascular System and Disorders

They have a greater prevalence of obesity, dyslipidemia, metabolic syndrome and diabetes mellitus. Higher risk of myocardial infarction, heart failure and atrial fibrillation was noted in spinal cord injury survivors compared to controls. Survivors with severe disability had the highest risk. Am J Phys Med Rehabil. 2023.12.010.

article thumbnail

Abstract 13: Prior Bariatric Surgery is Associated With Reduced Risk of Recurrent Stroke Among Elderly Obese Stroke Survivors: A National Inpatient Sample Study (2016-2019)

Stroke Journal

Introduction:The paucity of large-scale data exploring the effect of prior bariatric surgery on recurrent stroke outcomes in elderly obese stroke survivors led us to address the gap, with an emphasis on the risk of recurrent stroke and its trends.Methods:A retrospective study was conducted using National Inpatient Sample data from 2016-2019.

Obesity 40
article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52
article thumbnail

Empagliflozin: primum inter pares among sodium-glucose cotransporter-2 inhibitors?

Journal of Cardiovascular Pharmacology

Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.

article thumbnail

Plasma Protein Profiling of Incident Cardiovascular Diseases: A Multisample Evaluation

Circulation: Genomic and Precision Medicine

Our primary CVD outcome was defined by a combined end point that included either incident myocardial infarction, stroke, or heart failure.Results:Using a discovery/validation approach, 42 proteins were associated with our primary composite end point occurring in 1163 subjects. Thirteen proteins were related to all 3 outcomes.

article thumbnail

Research Data from Minneapolis Heart Institute Foundation at ACC 2024 Reveal Trends in Cardiovascular Risk Factors and Preventive Medication Use Prior to Heart Attacks

DAIC

The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardial infarction (STEMI), the most severe form of a heart attack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), 24), being held April 6-8 in Atltanta, GA.